Matthew Selmon, MD, FACC
Dr. Matthew Selmon is a native Texan who spent 22 years in the San Francisco Bay area as a practicing cardiologist, clinical researcher, and cofounder of Lumend, maker of the Frontrunner and Outback total occlusion devices now sold by J&J Cordis. Dr. Selmon earned his medical degree at Southwestern Medical School in Dallas, Texas. He went on to complete a cardiology fellowship at University of Missouri in Columbia, Missouri. He then completed a second fellowship in Interventional Cardiology at Sequoia Hospital in Redwood City, California. He is Board Certified in Internal Medicine, Cardiovascular Disease, and Interventional Cardiology. While practicing cardiology in California, Dr. Selmon partnered with world renowned cardiologist, Dr. John Simpson, on the coronary and peripheral device development company, Lumend, where he also worked as Chief Medical Officer. After Lumend was acquired in 2005 by J&J Cordis, Dr. Selmon returned to Texas to practice cardiology at Austin Heart, specializing in Interventional Cardiology, Peripheral Vascular Intervention, and Venous Disease with a special interest in chronic total occlusions (CTOs). He established Austin Heart’s new Vein Center in 2010 and currently serves as the Medical Director as he continues his work in coronary and peripheral vascular intervention. Dr. Selmon served as the national Principal Investigator for the CONNECT II Ocelot Trial, a new OCT directed peripheral chronic total occlusion device, and recently presented the findings at the VIVA Late Breaking Clinical Trials session.
